CCR1

This article will continue to review the antitumor targets of the GPCR family and the therapeutic drugs that have been marketed. 03 CXCR4The chemotactic properties of chemokines enable them to guide immune effector cells to sites of inflammation and coordinate interactions between immune cells. To date, approximately 50 human chemokines and 20 receptors have been identified. Chemokines can be classified into two categories based on their function: inflammatory chemokines and homeostatic chemokines. They can also be categorized according to the position of the first two cysteine (C) residues in their protein sequence. There are four classes of chemokines: CC chemokines, CXC chemokines, C chemokines, and CX3C chemokines. Taking chemokine CXCL12 (also known as stromal cell-derived factor-1, SDF-1) as an example, its interaction with the downstream receptor CXCR4 triggers downstream signaling pathways, impacting gene expression, cell chemotaxis, proliferation, and migration comprehensively. The CXCL12-CXCR4 signaling axis also plays a central role in tumor cell proliferation, angiogenesis, invasion, tumor microenvironment, and drug resistance induced by chemotherapy. Plerixafor, developed by Genzyme Corp., is the first selective reversible CXCR4 antagonist small molecule compound. It is used in combination with granulocyte colony-stimulating factor (G-CSF) to mobilize hematopoietic stem cells from the bone marrow to peripheral blood, facilitating their collection for autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. CXCR4 binding to its ligand SDF-1α is involved in the homing and transportation of CD34+ cells to the bone marrow. Plerixafor disrupts this interaction, leading to increased levels of CD34+ cells in peripheral blood. Plerixafor was granted orphan drug status in the USA and EU and received FDA approval in December 2008. The development history of Plerixafor originated from initial attempts to develop therapeutic drugs for HIV. After a series of optimizations and modifications, Plerixafor demonstrated strong selectivity for CXCR4. However, Plerixafor's competitive binding ability to CXCL12 remains weak (Ki approximately 650nM). Nevertheless, Plerixafor may induce severe hypersensitivity reactions such as anaphylactic responses. When used in leukemia patients, it can cause mobilization of tumor cells, splenic enlargement and rupture, embryotoxicity and fetotoxicity, and hematological effects such as leukocytosis and thrombocytopenia. AMD11070 is a small molecule CXCR4 antagonist for oral use, originally developed by AnorMED. Initially, it was designed to combat HIV infections. AMD11070 specifically targets the X4 strain of HIV-1, which relies on the CXCR4 receptor. It has been shown that AMD11070 binds to the CXCR4 receptor and blocks its interaction with SDF-1α. Moreover, it inhibits calcium signaling induced by SDF-1, with an IC50 of 9.0 ± 2.0 nM, and inhibits SDF-1α-induced cell chemotaxis, with an IC50 of 19.0 ± 4.0 nM. It is noteworthy that AMD11070 exhibits high selectivity for CXCR4, not inhibiting the downstream calcium signaling in cells expressing CXCR3, CCR1, CCR2b, CCR4, CCR5, or CCR7, nor does it inhibit ligand binding of CXCR7 or BLT1. Subsequently, Genzyme Corporation undertook the development of AMD11070 (Mavorixafor) for various clinical indications over a span of 10 years. In April 2024, Mavorixafor was approved by the FDA in the USA for the treatment of WHIM syndrome and chronic neutropenia. Additionally, Mavorixafor is also being developed for clinical indications such as triple-negative breast cancer. Motixafortide is another selective CXCR4 antagonist, developed by BioLineRx, for mobilizing hematopoietic stem cells (HSCs) and treating certain types of cancer. It was approved by the U.S. FDA on September 11, 2023, to be used in combination with Filgrastim (a granulocyte colony-stimulating factor, G-CSF) for mobilizing HSCs to peripheral blood, facilitating autologous transplantation for patients with multiple myeloma during a stem cell mobilization (SCM) process. Regarding efficacy data: In two single-collection procedures, the combined treatment of Motixafortide with G-CSF enabled 67.5% of patients to achieve the target of ≥6 million CD34+ cells/kg per collection, compared to only 9.5% in the placebo plus G-CSF group. In terms of safety: The Motixafortide plus G-CSF regimen generally demonstrated good tolerability and safety profile. The most common adverse reactions (incidence >20%) in the GENESIS trial included injection site reactions (pain, erythema, and pruritus), pruritus, flushing, and back pain. Regarding other potential applications: Motixafortide has been granted orphan drug status in the EU and the USA for the treatment of pancreatic cancer and in the USA for the treatment of acute myeloid leukemia. 04 Histamine 2R (H2R)Histamine is an endogenous biogenic amine that is widely distributed throughout the body, involved in many physiological and pathological conditions. Histamine exerts its effects through four histamine receptor subtypes (H1-H4) belonging to the GPCR family. Histamine is one of the major mediators involved in inflammation and immune responses. The primary cellular sources of histamine include mast cells, basophils, histaminergic neurons, and enterochromaffin-like cells in the gastrointestinal tract, with smaller amounts also being released by epithelial cells or T cells. Additionally, high levels of histamine and its receptors in various types of cancers suggest their involvement in the complex biological processes of cancer. The expression of histamine receptors in multiple human cancer cell lines supports the role of histamine as an autocrine growth factor, which increases cell proliferation rates. Furthermore, histamine can stimulate various events associated with carcinogenesis, such as cell invasion, migration, and angiogenesis, demonstrating its critical role in cancer progression. Some HR antagonists, as well as inhibitors of histamine synthesis or transport, have been reported to have preventive effects on the growth of cancer cells. The H2 histamine receptor (H2R) plays an important physiological role in the human body, particularly in regulating gastric acid secretion. Activation of H2R can promote the production of stomach acid. Therefore, H2R antagonists, such as cimetidine, ranitidine, and famotidine, are widely used to treat diseases related to excess stomach acid, such as gastric ulcers and duodenal ulcers. Famotidine, developed later and approved by the FDA in 1985, has a higher affinity for the H2 receptor than cimetidine and ranitidine, potentially offering stronger gastric acid suppression. Famotidine is also used to treat gastric ulcers, duodenal ulcers, GERD, and can be used to prevent and treat upper gastrointestinal bleeding. Compared to cimetidine, famotidine has fewer drug interactions and milder side effects. H2R antagonists are not first-line medications for cancer treatment. However, in cancer patients undergoing chemotherapy or radiotherapy, H2 receptor antagonists may be used to prevent or treat nausea and vomiting induced by the treatment, or to reduce the risk of upper gastrointestinal bleeding. How to obtain the latest research advancements in the field of biopharmaceuticals? In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

Promising feasibility study results for imaging technology that identified malignant peritoneal tumor metastasis during surgery NEWTON, Mass.--(BUSINESS WIRE)-- Lumicell Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced promising initial data from its ongoing feasibility study for lead candidate LUMISIGHT™ to detect peritoneal malignancies during surgical debulking. The ongoing study is utilizing the investigational LUMISIGHT optical imaging drug and accompanying imaging device to distinguish tumor metastases to organs within the peritoneum. The initial results from adult patients were shared in a podium presentation by James C. Cusack, Jr. MD, Associate Professor of Surgery at Massachusetts General Hospital, at the Advanced Cancer Therapies meeting organized by the Society of Surgical Oncology. “This data advances the potential for image-guided surgery to detect small tumors and metastases to organs in the peritoneal cavity which could provide better outcomes for our patients,” said Dr. Cusack. “Further innovation is desperately needed to improve the benefits of cytoreductive surgery for this invasive and elusive cancer. We look forward to continuing the clinical development program with Lumicell and advancing patient care.” The presence of peritoneal metastases has a significant negative impact on survival for patients. One of the most important determinants of treatment success and long-term overall survival is the ability to achieve removal of all visible cancer during initial surgery prior to the heated chemotherapy for a complete cytoreduction.2-5 “We are highly encouraged by this initial data in a promising new indication, as we continue to expand the development of LUMISIGHT across the spectrum of solid tumors. Everything we do at Lumicell is focused on improving surgical outcomes for patients,” said Howard Hechler, President of Lumicell. About Peritoneal Surface Malignancies and Metastasis Peritoneal surface malignancies include primary peritoneal malignant mesothelioma and tumors that have spread from different organs, referred to as peritoneal metastases. These metastases can originate from organs such as appendiceal, colorectal, gastric, pancreatic, and ovarian cancers, and affect more than 75,000 patients each year in the United States.1 The presence of disease and the extent of disease are often difficult to be fully evaluated by conventional non-invasive imaging techniques such as CT scan, PET scan, or MRI. Small peritoneal surface nodules are often detected at the time of surgical exploration by the surgeon’s eyes versus conventional imaging techniques. One of the most important determinants of treatment success and overall survival is the ability to achieve complete cytoreduction (CCR).2-5 While patients with no residual disease (CCR0) or minimal residual peritoneal surface tumor nodules less than 2.5 mm in maximum diameter (CCR1) have significantly better survival than those with residual nodules more than 2.5 mm in maximum diameter (CCR2), patients with CCR0 have experienced the best clinical outcomes.2,3,5 About Lumicell, Inc. Lumicell is a privately held company focused on the development and commercialization of innovative fluorescence-guided technologies for cancer surgery with the potential to improve patient outcomes and reduce healthcare costs. The company’s first products pending approval are LUMISIGHT™ and the Lumicell™ Direct Visualization System which, in combination, are designed to illuminate cancerous tissue during initial surgery potentially reducing the frequency of repeat surgeries. LUMISIGHT and the Lumicell Direct Visualization System are investigational products, both limited by federal law to investigational use only and are not commercially available. These products are currently under FDA review for their first indication in breast conserving surgery; and are also being explored across a wide variety of solid tumor indications to enhance the standard of care treatment by guiding the resection of additional cancer that may have otherwise been left behind. For more information, please visit or follow us at LinkedIn and X. Foster, J.M., Zhang, C., Rehman, S., Sharma, P. and Alexander, H.R. (2023), The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future. CA A Cancer J Clin, 73: 49-71. Elias, D., F. Quenet, and D. Goere, Current status and future directions in the treatment of peritoneal dissemination from colorectal carcinoma. Surg Oncol Clin N Am, 2012. 21(4): p. 611-23. Glockzin, G. and P. Piso, Current status and future directions in gastric cancer with peritoneal dissemination. Surg Oncol Clin N Am, 2012. 21(4): p. 625-33. Helm, C.W., Current status and future directions of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of ovarian cancer. Surg Oncol Clin N Am, 2012. 21(4): p. 645-63. Votanopoulos, K.I., et al., Current status and future directions in appendiceal cancer with peritoneal dissemination. Surg Oncol Clin N Am, 2012. 21(4): p. 599-609. Chan, C.H., et al., Preclinical Evaluation of Cathepsin-Based Fluorescent Imaging System for Cytoreductive Surgery. Ann Surg Oncol, 2017. 24(4): p. 931-938.

Guiding principles for a sustainable future: Invest in strategic therapeutic areas of oncology and immunologyRebuild and accelerate portfolio of transformational medicines in high unmet medical needsCombine internal with external innovation Capital allocation: Discontinue fibrosis and kidney disease to further invest in oncologyLeverage strong balance sheet through disciplined cash management and smart business development Oncology roadmap: Validate point-of-care CAR-T delivery model with proven CD191 and BCMA2Develop next-generation, best-in-class oncology candidates Immunology roadmap: Evaluate potential of filgotinib in axial spondyloarthritisExecute on TYK2i clinical program with ‘3667 Continue to invest in deep portfolio across modes of action, with JAKi, TYK2i and SIKi programs Commercial roadmap: Jyseleca® 2022 net sales guidance further upped to €80-€90 millionLeverage commercial infrastructure for future launches Webcast replay available at www.glpg.com Mechelen, Belgium; 4 November 2022, 21.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today held its R&D Day 2022, featuring presentations of key opinion leaders and company management on the strategic, scientific, and commercial progress at the company. The company also presented its financial results for the third quarter of 2022. Paul Stoffels3, CEO and Chairman of the Board of Directors of Galapagos, commented: “Today we presented our strategic vision for our future as a financially sustainable biopharma company. Building on our strong fundamentals, we are convinced that we are taking the right steps to deliver on our core mission: adding years of life and improving the quality of life of patients globally. Focusing on our strategic therapeutic areas, we strive to push forward our deep, differentiated portfolio in immunology, build out our oncology franchise, and execute on business development opportunities with the aim to accelerate innovation and speed up time-to-patients, while creating long-term value for our stakeholders.” Strategic update Building on our strong fundamentals, we aim to build a financially sustainable biopharma company, accelerating cutting-edge therapies to market to address unmet medical needs in our core key therapeutic areas of oncology and immunology. Our renewed focus on two strategic therapeutic areas goes hand in hand with redirecting our resources. To further streamline our portfolio, we have decided to discontinue activities in fibrosis and kidney disease to allow for increased investments in our oncology franchise. To shape our portfolio of innovative drugs with accelerated time-to-market, we intend to combine internal innovation with smart business development and apply deep clinical expertise to push programs through an optimal development process. Based on these guiding principles, we presented our Vision 2028 portfolio outlook. Over the course of the next five years, we aim to build a portfolio comprising: over 10 assets in lead optimization and five in preclinical development across different modalities (small molecules, cell therapy, biologics),five pivotal-stage candidates forming a solid late-stage pipeline in immunology and cell therapy, anda growing commercial presence with additional marketed indications for Jyseleca® and one CAR-T therapy approved in multiple indications. Financial vision Aligned with our Vision 2028, we presented our financial outlook and capital allocation strategy at our R&D Day 2022. Discontinuation of our fibrosis and kidney efforts allows for reinvesting in oncology. With Jyseleca® potentially breaking even in 2024, and projected peak sales of €500 million in Europe and first oncology revenues potentially contributing to our topline later this decade, we are committed to building a sustainable financial future, with a significantly reduced cash burn by 2028. Oncology We also presented our Vision 2028 roadmap for oncology at our R&D Day 2022. Our core mission in the field is to broaden patient access and improve clinical outcomes by bringing best-in-class medicines to patients. With the combined acquisitions of CellPoint and AboundBio announced earlier this year, we positioned ourselves in the cell therapy space, combining the potentially disruptive manufacturing and delivery model of CellPoint (Lonza’s Cocoon®, a closed, automated manufacturing platform for cell therapy) with the ability to develop next-generation CAR-Ts, small molecules and biologics. Short term, our aim is to validate the decentralized CAR-T delivery model with proven CAR-T therapies, and we announced the addition of a BCMA Phase 1/2 trial on the Cocoon® platform. This complements the currently ongoing CD19 Phase1/2 programs in recurring/refractory Non-Hodgkin Lymphoma (rrNHL; ATALANTA study) and recurring/refractory Chronic Lymphocytic Leukemia (rrCLL; EUPLAGIA study). In the coming years, we intend to build a pipeline of best-in-class cell therapies for hematologic malignancies and leverage our capabilities to rapidly address unmet needs in oncology. Today, we showcased the robust process performance of the Cocoon® system as well as first encouraging biomarker patient data of the CAR-T expansion profile with a 7 day-point-of-care vein-to-vein treatment. Topline Phase 1 results of both the rrNHL and rrCLL study are expected in the first half of 2023, followed by initial data of the BCMA study later in the year. Next year, we also aim to broaden the studies to include U.S. patients, and we plan to submit Investigational New Drug (IND) applications for both the CD19 and BCMA CAR-T programs with the FDA. Immunology We have built up over 20 years of expertise in immunology, resulting in a deep and growing pipeline with multiple modes-of-action candidate medicines across all phases of development, from preclinical to Phase 4. We are excited about our selective TYK2 inhibitor, ‘3667, for which we presented new data elucidating its potentially differentiating selectivity and potency profile. Ex vivo and in vivo data show that ‘3667 fully blocks the INFa pathway with once-daily dosing, while in our assays JAK2 and JAK1/3 dependent pathways are not affected. Further, no effects on hematological parameters, lipids and creatine phosphokinase (CPK) were observed, suggesting that ‘3667 does not show JAKi ‘fingerprints’ at therapeutic doses. Also based on the positive results in psoriasis patients, we presented our development plan for ‘3667, confirming the start of a Phase 2 study in dermatomyositis (GALARISSO) around year-end and the intention to start a Phase 2 study in systemic lupus erythematosus (SLE) in 2023. We also presented an update on our SIKi portfolio, a potential novel mode-of-action in immunology. With targeted investments, we continue to make important progress in developing next-generation best-in-class candidates that reach optimal target coverage, teasing apart selectivity profiles that indicate the potential of SIK3i for rheumatological indications and SIK2/3i for inflammatory bowel disease. Our most advanced candidate, SIK3 inhibitor ‘4399, has shown strong preclinical evidence for potential in rheumatoid arthritis (RA) (EULAR 20224), with a promising pharmacological and safety profile. We are planning to start a proof-of-mechanism study in RA patients with ‘4399 mid 2023. For filgotinib, our selective JAK1 inhibitor, we are completing a Phase 3 program in Crohn’s disease (CD), with results expected in the first half of 2023. Given the sales momentum and supportive long-term safety and efficacy data generated for filgotinib, we are currently exploring additional indications for filgotinib, and plan to start a Phase 3 study in axial spondyloarthritis (AxSpA) in 2023. Commercial progress Since becoming European marketing authorization holder (MAH) of Jyseleca®, we successfully set up our own commercial capabilities and are currently operational throughout Europe in the current approved indications RA and ulcerative colitis (UC). The financial results for the third quarter of 2022 show continued strong sales momentum for Jyseleca®, and we further raise our net sales guidance 2022 from €75-€85 million at H1 2022 to €80-€90 million. In the future, we aim to leverage our European commercial infrastructure beyond Jyseleca®, in line with our Vision 2028, to have at least one CAR-T cell therapy on the market within five years. Jyseleca® is a trademark of Galapagos NV and Gilead Sciences, Inc. or its related companies. Except for filgotinib’s approval as Jyseleca® for the treatment of moderately to severely RA and UC by the relevant regulatory authorities in the European Union, Great Britain, and Japan, our drug candidates are investigational; their efficacy and safety have not been fully evaluated by any regulatory authority. About GalapagosGalapagos is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients’ lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 4 programs in immunology, oncology, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is available in the European Union, Norway, Great Britain, and Japan. For additional information, please visit www.glpg.com or follow us on LinkedIn or Twitter. ContactInvestors:Sofie Van GijselHead of Investor Relations+1 781 296 1143 Sandra CauwenberghsDirector Investor Relations+32 495 58 46 63ir@glpg.com Media:Marieke VermeerschHead of Corporate Communication+32 479 490 603media@glpg.com Forward-looking statements This press release contains forward-looking statements, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “expect,” “intend,” “plan,” “future,” “estimate,” “may,” “potential,” “forward,” “next,” “continue,” “promise” “encouraging,” “aim,” “explore,” “further” as well as similar expressions. These statements include, but are not limited to, statements made in the sections captioned “strategic update,” “financial vision,” “commercial progress,”, the guidance from management (including the guidance regarding the expected operational use of cash during the 2022 fiscal year, the expected financial results and our strategic and capital allocation priorities), statements regarding the acquisitions of CellPoint and AboundBio, including statements regarding anticipated benefits of the acquisitions and the integration of CellPoint and AboundBio into our portfolio and strategic plans, statements regarding our regulatory and R&D outlook, statements regarding our expected financial results, statements regarding the amount and timing of potential future milestones, opt-in and/or royalty payments, our R&D strategy, including progress on our immunology or oncology portfolio or our JAKi, TYK2i and SIKi programs, and potential changes in such strategy, statements regarding our pipeline and complementary technology platforms driving future growth, statements regarding our expectations on commercial sales of filgotinib, statements regarding the global R&D collaboration with Gilead and the amendment of our arrangement with Gilead for the commercialization and development of filgotinib, statements regarding the expected timing, design and readouts of ongoing and planned clinical trials, including topline results for trials and studies in our portfolio, statements about the expected topline results from the DIVERSITY Phase 3 study in CD, statements relating to interactions with regulatory authorities, the timing or likelihood of additional regulatory authorities’ approval of marketing authorization for filgotinib for RA, UC or other indications for filgotinib in Europe, Great Britain, Japan, and the U.S., such additional regulatory authorities requiring additional studies, the timing or likelihood of pricing and reimbursement interactions for filgotinib, statements relating to the build-up of our commercial organization, commercial sales for filgotinib and rollout in Europe, statements related to the expected reimbursement for Jyseleca®, and statements regarding our strategy (including our strategic transformation exercise), portfolio goals, business plans, focus, and plans for a sustainable future. We caution the reader that forward-looking statements are based on our management’s current expectations and beliefs, and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause our actual results, financial condition and liquidity, performance or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Such risks include, but are not limited to, the risk that our expectations regarding our 2022 revenues and financial results or our 2022 operating expenses may be incorrect (including because one or more of our assumptions underlying our revenue or expense expectations may not be realized), the risk that ongoing and future clinical trials may not be completed in the currently envisaged timelines or at all, the inherent risks and uncertainties associated with competitive development, clinical trial, recruitment of patients for trials and product development activities and regulatory approval requirements (including, but not limited to, the risk that data from our ongoing and planned clinical research programs in RA, rrNHL, rrCLL, CD, UC, axial spondyloarthritis, dermatomyositis, systemic lupus erythematosus, other immunologic indications or other indications or diseases, may not support registration or further development of our product candidates due to safety, or efficacy concerns, or other reasons), risks related to the acquisitions of CellPoint and AboundBio, including the risk that we may not achieve the anticipated benefits of the acquisitions of CellPoint and AboundBio, the inherent risks and uncertainties associated with target discovery and validation and drug discovery and development activities, risks related to our reliance on collaborations with third parties (including our collaboration partner for filgotinib, Gilead), risks related to the implementation of the transition of the European commercialization responsibility of filgotinib from Gilead to us, the risk that the transition will not be completed on the currently contemplated timeline or at all, including the transition of the supply chain, and the risk that the transition will not have the currently expected results for our business and results of operations, estimating the commercial potential of our product candidates and our expectations regarding the costs and revenues associated with the transfer of the European commercialization rights to filgotinib may be incorrect, the risk that we will not be able to continue to execute on our currently contemplated business plan and/or will revise our business plan, including the risk that our plans with respect to CAR-T may not be achieved on the currently anticipated timeline or at all, the risk that our projections and expectations regarding the commercial potential of our product candidates or expectations regarding the costs and revenues associated with the commercialization rights may be inaccurate, the risks related to our strategic transformation exercise, including the risk that we may not achieve the anticipated benefits of such exercise on the currently envisaged timeline or at all, the risk that we will encounter challenges retaining or attracting talent, risks related to disruption in our operations, supply chain or ongoing studies (including our DIVERSITY 1 study) due to the conflict between Russia and Ukraine, the risks related to continued regulatory review of filgotinib following approval by relevant regulatory authorities and the European Medicines Agency’s (EMA) safety review of JAK inhibitors used to treat certain inflammatory disorders, including the risk that the EMA and/or other regulatory authorities determine that additional non-clinical or clinical studies are required with respect to filgotinib, the risk that the EMA may require that the market authorization for filgotinib in the EU be amended, the risk that the EMA may impose JAK class-based warnings, the risk that the EMA’s safety review may negatively impact acceptance of filgotinib by patients, the medical community, and healthcare payors and the risks and uncertainties related to the impact of the COVID-19 pandemic. A further list and description of these risks, uncertainties and other risks can be found in our filings and reports with the Securities and Exchange Commission (SEC), including in our most recent annual report on Form 20‐F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation. 1 Cluster of differentiation 192 B-cell maturation antigen3 Acting via Stoffels IMC BV4 Poster presented at EULAR (European Alliance of Associations for Rheumatology) 2022, POS0442 Attachment Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022